Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias.

The calcium-sensing receptor (CaSR) is a widely expressed G protein-coupled receptor (GPCR) that mediates numerous tissue-specific functions. Its multiple ligands and diverse roles attest to the need for exquisite control over the signaling pathways that mediate its effects. 'Biased signaling' is the phenomenon by which distinct ligands stabilize preferred receptor signaling states. The CaSR is subject to biased signaling in response to its endogenous ligands. Interestingly, the 'natural' bias of the CaSR is altered in disease states, and small molecule drugs engender biased allosteric modulation of downstream signaling pathways. Thus, biased signaling from the CaSR also has important implications pathophysiologically and therapeutically. As outlined in this review, this novel paradigm extends to other GPCRs, making the CaSR a model for studies of ligand-biased signaling and for understanding how it may be used to foster selective drug activity in different tissues.

[1]  P. Sexton,et al.  Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium-sensing receptor. , 2012, Endocrinology.

[2]  J. Violin,et al.  Biased ligands at G-protein-coupled receptors: promise and progress. , 2014, Trends in pharmacological sciences.

[3]  K. Schmelzer,et al.  Characterization of Highly Efficacious Allosteric Agonists of the Human Calcium-Sensing Receptor , 2011, Journal of Pharmacology and Experimental Therapeutics.

[4]  Lisa Nguyen,et al.  Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance , 2010, Journal of Pharmacology and Experimental Therapeutics.

[5]  P. White,et al.  Delineating the Mode of Action of Adenosine A1 Receptor Allosteric Modulators , 2010, Molecular Pharmacology.

[6]  Yoshihiro Kubo,et al.  Ligand-induced rearrangement of the dimeric metabotropic glutamate receptor 1α , 2004, Nature Structural &Molecular Biology.

[7]  J. Parma,et al.  The thyrotropin receptor and the regulation of thyrocyte function and growth. , 1992, Endocrine reviews.

[8]  J. Violin,et al.  β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection , 2007 .

[9]  S. Garland.  Are GPCRs Still a Source of New Targets? , 2013, Journal of biomolecular screening.

[10]  Alex R. B. Thomsen,et al.  Biased agonism of the calcium-sensing receptor. , 2012, Cell calcium.

[11]  J. Atherton,et al.  Arg389Gly-&bgr;1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol , 2007, Pharmacogenetics and genomics.

[12]  Carlo Lombardi,et al.  Role of Beta-Adrenergic Receptor Gene Polymorphisms in the Long-Term Effects of Beta-Blockade with Carvedilol in Patients with Chronic Heart Failure , 2010, Cardiovascular Drugs and Therapy.

[13]  P. Sexton,et al.  Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties , 2010, Neuropsychopharmacology.

[14]  A. Conigrave,et al.  The Venus Fly Trap domain of the extracellular Ca2+ -sensing receptor is required for L-amino acid sensing. , 2004, The Journal of biological chemistry.

[15]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[16]  G. Christ,et al.  Ca2+-induced increases in steady-state concentrations of intracellular calcium are not required for inhibition of parathyroid hormone secretion. , 1999, Molecular cell biology research communications : MCBRC.

[17]  J. Galzi,et al.  A novel, conformation‐specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Mayako Michino,et al.  Improved model building and assessment of the Calcium‐sensing receptor transmembrane domain , 2008, Proteins.

[19]  C. Ram,et al.  Beta-blockers in hypertension. , 2010, The American journal of cardiology.

[20]  A. Lania,et al.  Mitogen-activated protein kinase cascade in human normal and tumoral parathyroid cells. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  A. Christopoulos,et al.  Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with L-amino acids. , 2011, The Journal of biological chemistry.

[22]  K. Ahn,et al.  Allosteric Modulator ORG27569 Induces CB1 Cannabinoid Receptor High Affinity Agonist Binding State, Receptor Internalization, and Gi Protein-independent ERK1/2 Kinase Activation* , 2012, The Journal of Biological Chemistry.

[23]  J. Nakae,et al.  Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. , 2002, The Journal of clinical endocrinology and metabolism.

[24]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[25]  Didier Rognan,et al.  Positive and Negative Allosteric Modulators of the Ca2+-sensing Receptor Interact within Overlapping but Not Identical Binding Sites in the Transmembrane Domain* , 2004, Journal of Biological Chemistry.

[26]  S. Nakanishi,et al.  Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor , 2000, Nature.

[27]  G. Hendy,et al.  Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. , 2011, The Journal of clinical endocrinology and metabolism.

[28]  P. Sexton,et al.  Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. , 2012, Endocrinology.

[29]  B. Lutz,et al.  Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[30]  P. Sexton,et al.  Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. , 2013, Endocrinology.

[31]  L. Prézeau,et al.  Closure of the Venus flytrap module of mGlu8 receptor and the activation process: Insights from mutations converting antagonists into agonists , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Christopoulos,et al.  Roles of intraloops‐2 and ‐3 and the proximal C‐terminus in signalling pathway selection from the human calcium‐sensing receptor , 2014, FEBS letters.

[33]  Y. Takeuchi,et al.  Association between activating mutations of calcium-sensing receptor and Bartter's syndrome , 2002, The Lancet.

[34]  A. Cassio,et al.  Current Loss-of-Function Mutations in the Thyrotropin Receptor Gene: When to Investigate, Clinical Effects, and Treatment , 2012, Journal of clinical research in pediatric endocrinology.

[35]  M. Bouvier,et al.  Conformational Rearrangements and Signaling Cascades Involved in Ligand-Biased Mitogen-Activated Protein Kinase Signaling through the β1-Adrenergic Receptor , 2008, Molecular Pharmacology.

[36]  S. Shakir,et al.  An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making , 2014, BMJ Open.

[37]  D. Devost,et al.  A Novel Biased Allosteric Compound Inhibitor of Parturition Selectively Impedes the Prostaglandin F2α-mediated Rho/ROCK Signaling Pathway* , 2010, The Journal of Biological Chemistry.

[38]  D. Rognan,et al.  Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor* , 2003, Journal of Biological Chemistry.

[39]  S. H. Young,et al.  Amino acids and Ca2+ stimulate different patterns of Ca2+ oscillations through the Ca2+-sensing receptor. , 2002, American journal of physiology. Cell physiology.

[40]  A. Conigrave,et al.  Broad-spectrum amino acid-sensing class C G-protein coupled receptors: molecular mechanisms, physiological significance and options for drug development. , 2010, Pharmacology & therapeutics.

[41]  R. Wolf,et al.  Homology Modeling of the Transmembrane Domain of the Human Calcium Sensing Receptor and Localization of an Allosteric Binding Site* , 2004, Journal of Biological Chemistry.

[42]  J. Bockaert,et al.  GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells , 2009, The Journal of Biological Chemistry.

[43]  E. Brown,et al.  Role of the calcium-sensing receptor in extracellular calcium homeostasis. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[44]  P. Sexton,et al.  Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects , 2012, Molecular Pharmacology.

[45]  Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor. , 1997, The Journal of clinical endocrinology and metabolism.

[46]  Christopher G. Tate,et al.  Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol , 2012, Structure.

[47]  J. Prestegard,et al.  Direct Determination of Multiple Ligand Interactions with the Extracellular Domain of the Calcium-sensing Receptor* , 2014, The Journal of Biological Chemistry.

[48]  S. Morony,et al.  Discovery of a Calcimimetic with Differential Effects on Parathyroid Hormone and Calcitonin Secretion , 2011, Journal of Pharmacology and Experimental Therapeutics.

[49]  J. Changeux,et al.  International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands , 2014, Pharmacological Reviews.

[50]  S. Refetoff,et al.  A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis. , 2007, The Journal of clinical endocrinology and metabolism.

[51]  Stuart Maudsley,et al.  β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. , 2013, Molecular endocrinology.

[52]  S. H. Young,et al.  Requirement of the TRPC1 Cation Channel in the Generation of Transient Ca2+ Oscillations by the Calcium-sensing Receptor* , 2006, Journal of Biological Chemistry.

[53]  E. Brown,et al.  Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. , 1991, Physiological reviews.

[54]  K. Schlingmann,et al.  Autosomal Dominant Hypoparathyroidism with Severe Hypomagnesemia and Hypocalcemia, Successfully Treated with Recombinant PTH and Continuous Subcutaneous Magnesium Infusion , 2008, Journal of pediatric endocrinology & metabolism : JPEM.

[55]  C. Langmead,et al.  Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia , 2011, Molecular Pharmacology.

[56]  E. Brown,et al.  A novel gain-of-function mutation (F821L) in the transmembrane domain of calcium-sensing receptor is a cause of severe sporadic hypoparathyroidism , 2004, European Journal of Pediatrics.

[57]  Joanne Baltos,et al.  Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist , 2014, Proceedings of the National Academy of Sciences.

[58]  Arthur Christopoulos,et al.  Quantification of Ligand Bias for Clinically Relevant β2-Adrenergic Receptor Ligands: Implications for Drug Taxonomy , 2014, Molecular Pharmacology.

[59]  Heather J. Lee,et al.  Allosteric activation of the extracellular Ca2+-sensing receptor by L-amino acids enhances ERK1/2 phosphorylation. , 2007, The Biochemical journal.

[60]  Steven H Young,et al.  Amino Acid-stimulated Ca2+ Oscillations Produced by the Ca2+-sensing Receptor Are Mediated by a Phospholipase C/Inositol 1,4,5-Trisphosphate-independent Pathway That Requires G12, Rho, Filamin-A, and the Actin Cytoskeleton* , 2005, Journal of Biological Chemistry.

[61]  G. Labesse,et al.  Interdomain movements in metabotropic glutamate receptor activation , 2011, Proceedings of the National Academy of Sciences.

[62]  P. Dauban,et al.  Calindol, a Positive Allosteric Modulator of the Human Ca2+ Receptor, Activates an Extracellular Ligand-binding Domain-deleted Rhodopsin-like Seven-transmembrane Structure in the Absence of Ca2+* , 2005, Journal of Biological Chemistry.

[63]  D. Riccardi,et al.  The calcium-sensing receptor beyond extracellular calcium homeostasis: conception, development, adult physiology, and disease. , 2012, Annual review of physiology.

[64]  C. Lindsley,et al.  Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity , 2009, Molecular Pharmacology.

[65]  J. Walsh,et al.  Novel mutations in the calcium‐sensing receptor gene associated with biochemical and functional differences in familial hypocalciuric hypercalcaemia , 2006, Clinical endocrinology.

[66]  Shailesh N Mistry,et al.  Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics , 2015, British journal of pharmacology.

[67]  D. Ward,et al.  Calcium-sensing receptor (CaSR): pharmacological properties and signaling pathways. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[68]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[69]  F. Locatelli,et al.  A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[70]  S. Pechhold,et al.  The extracellular calcium-sensing receptor is required for cholecystokinin secretion in response to L-phenylalanine in acutely isolated intestinal I cells. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[71]  A. Grant,et al.  Amino acids stimulate cholecystokinin release through the Ca2+-sensing receptor. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[72]  J. Northup,et al.  Evidence for Distinct Cation and Calcimimetic Compound (NPS 568) Recognition Domains in the Transmembrane Regions of the Human Ca2+ Receptor* , 2002, The Journal of Biological Chemistry.

[73]  D. Riccardi,et al.  An exon 5-less splice variant of the extracellular calcium-sensing receptor rescues absence of the full-length receptor in the developing mouse lung , 2011, Experimental lung research.

[74]  R. Lefkowitz,et al.  Recent developments in biased agonism. , 2014, Current opinion in cell biology.

[75]  P. Halban,et al.  Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-α and DUSP14 , 2008, Diabetes.

[76]  D. Coy,et al.  Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion , 2010, Proceedings of the National Academy of Sciences.

[77]  Alex R. B. Thomsen,et al.  Strontium Is a Biased Agonist of the Calcium-Sensing Receptor in Rat Medullary Thyroid Carcinoma 6-23 Cells , 2012, Journal of Pharmacology and Experimental Therapeutics.

[78]  S. Pearce,et al.  Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. , 1995, The Journal of clinical investigation.

[79]  J. Betka,et al.  Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene , 2009, European Journal of Pediatrics.

[80]  A. Christopoulos,et al.  Calcium-sensing receptor-dependent activation of CREB phosphorylation in HEK293 cells and human parathyroid cells. , 2013, American journal of physiology. Endocrinology and metabolism.

[81]  P. Sexton,et al.  Engendering biased signalling from the calcium‐sensing receptor for the pharmacotherapy of diverse disorders , 2014, British journal of pharmacology.

[82]  J. M. Mathiesen,et al.  Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2 , 2005, Molecular Pharmacology.

[83]  G. Hendy,et al.  A hypocalcemic child with a novel activating mutation of the calcium-sensing receptor gene: successful treatment with recombinant human parathyroid hormone. , 2006, The Journal of clinical endocrinology and metabolism.

[84]  P. Elias,et al.  The Calcium Sensing Receptor and Its Alternatively Spliced Form in Murine Epidermal Differentiation* , 2000, The Journal of Biological Chemistry.

[85]  P. Sexton,et al.  Prediction of Functionally Selective Allosteric Interactions at an M3 Muscarinic Acetylcholine Receptor Mutant Using Saccharomyces cerevisiae , 2010, Molecular Pharmacology.

[86]  J. Baron,et al.  Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. , 1996, Human molecular genetics.

[87]  S. H. Young,et al.  Amino acids and Ca 2 stimulate different patterns of Ca 2 oscillations through the Ca 2 -sensing receptor , 2002 .

[88]  R. Lefkowitz,et al.  A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation , 2009, Science Translational Medicine.

[89]  P. Sexton,et al.  Polymorphism and Ligand Dependent Changes in Human Glucagon-Like Peptide-1 Receptor (GLP-1R) Function: Allosteric Rescue of Loss of Function Mutation , 2011, Molecular Pharmacology.

[90]  E. Nemeth,et al.  Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[91]  H. Tanaka,et al.  Two novel missense mutations in calcium-sensing receptor gene associated with neonatal severe hyperparathyroidism. , 1997, The Journal of clinical endocrinology and metabolism.

[92]  B. Moats-Staats,et al.  A novel mutation (E767K) in the second extracellular loop of the calcium sensing receptor in a family with autosomal dominant hypocalcemia , 2005, American journal of medical genetics. Part A.

[93]  Arthur Christopoulos,et al.  Advances in G Protein-Coupled Receptor Allostery: From Function to Structure , 2014, Molecular Pharmacology.

[94]  R. Stevens,et al.  Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.

[95]  J. Dumont,et al.  Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. , 1992, Physiological reviews.

[96]  E. Brown,et al.  In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. , 1997, The Journal of clinical investigation.

[97]  P. Conn,et al.  Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes , 2005, Journal of Pharmacology and Experimental Therapeutics.

[98]  Bruce L. Booth,et al.  Opinion: Prospects for productivity , 2004, Nature Reviews Drug Discovery.